Safusidenib clinical trials
Also written DS-1001b.
How each study uses safusidenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the safusidenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2023 (2); 3 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Nuvation Bio Inc. (3) · Daiichi Sankyo Co., Ltd. (1) · Daiichi Sankyo (1) · University of Zurich (1) · AnHeart Therapeutics Inc. (1)
Studies
Open first, then newest update. How each study uses safusidenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseRecruitingPhase 2Nuvation Bio Inc.NCT07703436Written as Safusidenib
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)RecruitingPhase 3Nuvation Bio Inc.NCT05303519Written as safusidenib
- Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II StudyNot yet recruitingPhase 2University of ZurichNCT07832123Written as Safusidenib
- Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant GliomaNot yet recruitingPhase 3Nuvation Bio Inc.NCT07712757Written as Safusidenib
- A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II GliomaActive, not recruitingPhase 2Daiichi Sankyo Co., Ltd.NCT04458272Written as DS-1001b
- Study of DS-1001b in Patients With Gene IDH1-Mutated GliomasCompletedPhase 1Daiichi SankyoNCT03030066Written as DS-1001b
- IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid TumorTerminatedPhase 1AnHeart Therapeutics Inc.NCT05814536Written as AB-218 capsule
Codes
What other systems call safusidenib · ClinicalTrials.gg INT017788
- UNII (FDA) RCK8KK7SB9SAFUSIDENIBOne source FDA
- NCI Thesaurus C148134SafusidenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RCK8KK7SB9 | SAFUSIDENIB | One source FDA |
| NCI Thesaurus | C148134 | Safusidenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.